Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503837 | 0.87 | OPRD1 (0.44) | OPRD1KMT2AOPRM1 | |
| SCHEMBL5871033 | 0.87 | OPRD1 (0.44) | OPRD1KMT2AOPRM1 | |
| SCHEMBL7498243 | 0.87 | OPRD1 (0.44) | OPRD1KMT2AOPRM1 | |
| SCHEMBL7497373 | 0.85 | SLC6A2 (0.41) | EPHX2HPGDKMT2ACPN1CPB2 | |
| SCHEMBL7492223 | 0.83 | HTT (0.39) | OPRD1KMT2ACPN1CPB2TSHR | |
| SCHEMBL7498124 | 0.82 | OPRD1 (0.36) | OPRD1KMT2ABRD4CREBBPOPRM1 | |
| SCHEMBL5870866 | 0.81 | OPRM1 (0.41) | OPRD1OPRM1 | |
| SCHEMBL7501264 | 0.81 | OPRD1 (0.42) | EPHX2OPRD1KMT2AOPRM1 | |
| SCHEMBL5871117 | 0.80 | OPRD1 (0.42) | EPHX2OPRD1EPHX1OPRM1 | |
| SCHEMBL7493491 | 0.80 | OPRM1 (0.43) | OPRD1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946477-B2 | 3-Substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | AQUILA BRIAN M (US) | 2003-06-19 | — | — | US | disclosed |
| US-6476050-B2 | ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS | SEPRACOR, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001068604-A2 | 3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX2 1187/4885OPRD1 5/4885HPGD 490/4885 |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX2 1187/4885OPRD1 5/4885HPGD 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.